Skip to main navigation
Skip to main content

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • brazil
      Brazil
      • Portugues
    • france
      France
      • Français
    • germany
      Germany
      • Deutsch
    • Italian flag
      Italy
      • Italiano
    • japan
      Japan
      • Japanese
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • brazil
      Brazil
      • Portugues
    • france
      France
      • Français
    • germany
      Germany
      • Deutsch
    • Italian flag
      Italy
      • Italiano
    • japan
      Japan
      • Japanese
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English
Home

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Mucopolysaccharidosis Type IIIA
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Advocacy
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

Social Links

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Media Statements

  • Home
  • Investor Relations
  • Media Statements

IR Menu

IR Home
Press Releases
Events & Presentations
Corporate Governance
Stock Information
SEC Filings
Analyst Coverage
Information Request
FAQs

Tertiary Nav - Press Releases

  • Press Releases
  • Media Statements

Media Statements

Date Title
3/19/20 Sarepta’s Response to COVID-19

Toolkit

Print Page | Email Alerts | RSS Feeds | Contacts

Follow Us On Social

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Mucopolysaccharidosis Type IIIA
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Advocacy
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

©2021 Sarepta Therapeutics All rights reserved.

Footer Utility Nav

  • Privacy Policy
  • Terms of Use
  • EU-U.S. and Swiss-U.S. Privacy Shield Policy